CancerICD-10: C61About 288,000 new cases per year in the US; 1 in 8 men will be diagnosed in their lifetime

Prostate Cancer

Also known as: Prostatic Carcinoma, Prostate Adenocarcinoma

Prostate cancer is the most common cancer in men (excluding skin cancer) and develops in the prostate gland, a small walnut-shaped gland that produces seminal fluid. Many prostate cancers are slow-growing and may not cause significant harm, while others are aggressive and can spread rapidly. Screening with PSA testing and treatment decisions are highly individualized based on cancer grade, stage, age, and overall health.

Last updated November 10, 2026

Understanding Prostate Cancer

Prostate cancer is a malignant growth of the gland cells of the prostate, almost always an adenocarcinoma, and it is the most common non-skin cancer in American men. The American Cancer Society estimates about 313,000 new diagnoses and roughly 35,000 deaths in the United States in 2025, which makes it the second leading cause of cancer death in men after lung cancer. About 1 man in 8 will be diagnosed in his lifetime, but only around 1 in 44 will die of it, a gap that tells you most of what you need to know about this disease: much of it is slow. The median age at diagnosis is 67, it is rare before 40, and Black men are about 70 percent more likely to be diagnosed and roughly twice as likely to die from it as white men. A father or brother with the disease doubles your risk, and inherited BRCA2 mutations raise it several-fold and push it toward more aggressive forms.

Prostate cancer develops when gland cells accumulate mutations that let them grow without the normal checks, and in most cases that growth is driven by androgens, the male hormones testosterone and dihydrotestosterone. That dependence is why shutting off androgen signaling has been the backbone of treatment for advanced disease since the 1940s. Tumors are graded by how abnormal the cells look, now reported as Grade Group 1 (least aggressive) to 5, alongside the older Gleason score. Natural history varies enormously with grade. Autopsy studies find prostate cancer in about a third of men over 50 and more than half of men over 80 who died of something else, and Grade Group 1 disease almost never spreads within a decade. Higher grades grow faster and, when they spread, go first to pelvic lymph nodes and bone, which is why new, persistent back, hip or rib pain in a man with a rising PSA is taken seriously. Localized disease is usually silent; urinary symptoms are more often from benign enlargement.

Treatment is matched to risk. For low-risk disease, active surveillance is now the recommended approach in the AUA, NCCN and European guidelines, and the ProtecT trial is the reason: 1,643 British men with screen-detected localized cancer were randomized to active monitoring, surgery or radiotherapy, and after 15 years death from prostate cancer was about 3 percent in every group. Monitoring carried more metastases (9.4 percent versus about 5 percent) but spared most men the incontinence and erectile dysfunction of treatment. Intermediate and high-risk localized disease is treated with radical prostatectomy or radiotherapy, the latter often combined with months to years of androgen deprivation therapy (ADT). Metastatic disease is treated with ADT plus an androgen receptor pathway inhibitor such as abiraterone, enzalutamide, apalutamide or darolutamide, with docetaxel added for high-volume disease; later lines include cabazitaxel, PARP inhibitors for BRCA-mutated tumors, radium-223 for bone-only disease and lutetium-177 PSMA therapy, which extended survival by about 4 months in the VISION trial. Five-year survival is 99 percent for localized or regional disease and about 37 percent once it is distant.

No supplement, herb or diet treats prostate cancer, and the best-studied ones have either failed or caused harm. The SELECT trial, the largest cancer prevention trial ever run, randomized 35,533 men to vitamin E (400 IU a day), selenium (200 mcg), both or placebo; it was stopped early for futility, and on extended follow-up men who took vitamin E alone had a 17 percent higher rate of prostate cancer than men on placebo. Selenium did nothing and was linked to more diabetes in the first analysis. Saw palmetto does not shrink tumors or reliably change PSA, pomegranate juice failed two placebo-controlled trials, and lycopene supplements have never shown a convincing effect despite decades of interest. What remains is a short list of supportive measures with real evidence: vitamin D and calcium to protect bone during ADT, ginger to blunt chemotherapy nausea, and small, preliminary signals for green tea catechins in precancerous lesions and sulforaphane in men with a rising PSA after surgery. Treat these as adjuncts to be discussed with your oncologist, never as alternatives.

The most common mistake is at the two extremes. Some men rush low-risk Grade Group 1 cancer into surgery or radiation they do not need, accepting a real risk of incontinence and impotence to treat a tumor that would probably never have harmed them; the ProtecT data say surveillance is safe for most of these men as long as they actually keep up with the PSA tests, MRI scans and repeat biopsies that make it active rather than neglect. Others, told they have a slow cancer, decide to manage it with diet and supplements and stop showing up, which is how a treatable cancer becomes a metastatic one. A second, quieter mistake happens on ADT: men lose 2 to 4 percent of bone density a year in the first years, gain fat, lose muscle and become insulin resistant, yet many are never offered a bone density scan, calcium and vitamin D, or a resistance exercise plan. Ask for all three on the day ADT starts.

At a Glance

Common symptoms
Often asymptomatic in early stages, Difficulty urinating or weak urinary stream, Frequent urination, especially at night (nocturia)
Main treatments
Active surveillance for low-risk, slow-growing cancers, Radical prostatectomy (surgical removal of the prostate), Radiation therapy (external beam or brachytherapy)
Category
Cancer · About 288,000 new cases per year in the US; 1 in 8 men will be diagnosed in their lifetime
See a doctor if
Difficulty urinating, weak stream, or blood in urine

Symptoms

Often asymptomatic in early stages
Difficulty urinating or weak urinary stream
Frequent urination, especially at night (nocturia)
Blood in urine (hematuria) or semen
Erectile dysfunction
Pelvic, hip, or back pain (may indicate advanced disease)
Unexplained weight loss

Causes

  • Acquired genetic mutations in prostate cells (most cases)
  • Inherited gene mutations (BRCA2, HOXB13, Lynch syndrome genes)
  • Hormonal factors — testosterone and dihydrotestosterone (DHT) fuel prostate cancer growth

Risk Factors

  • Age over 50 (risk increases significantly with age)
  • African American men (highest incidence and mortality rates)
  • Family history of prostate cancer (father or brother doubles risk)
  • BRCA2 gene mutation carriers
  • Obesity (associated with more aggressive disease)
  • Diet high in red meat and high-fat dairy

Diagnosis

  • PSA (prostate-specific antigen) blood test
  • Digital rectal examination (DRE)
  • Multiparametric MRI of the prostate
  • Transrectal ultrasound-guided or MRI-targeted prostate biopsy
  • Gleason score / Grade Group for grading aggressiveness

Treatment

  • Active surveillance for low-risk, slow-growing cancers
  • Radical prostatectomy (surgical removal of the prostate)
  • Radiation therapy (external beam or brachytherapy)
  • Androgen deprivation therapy (ADT) for advanced disease
  • Chemotherapy (docetaxel) for metastatic castration-resistant prostate cancer
  • Targeted therapy (PARP inhibitors for BRCA-mutated cancers)

Natural remedies for prostate cancer: what the evidence says

Ranked by the strength of human evidence for prostate cancer specifically. These sit alongside medical care, not in place of it.

  1. Vitamin D

    Moderate evidence

    Androgen deprivation therapy cuts bone density by 2 to 4 percent a year initially and roughly doubles fracture risk, and vitamin D deficiency is common in men with prostate cancer, especially Black men and those on ADT. NCCN and ASCO guidance recommends 1,000 to 1,200 mg of calcium and 800 to 1,000 IU of vitamin D daily for men on ADT, with a bone density scan at the start and a bisphosphonate or denosumab when fracture risk is high. The evidence that vitamin D changes the cancer itself is weak: in an open-label study of 52 men on active surveillance taking 4,000 IU a day for a year, 55 percent had fewer positive cores at repeat biopsy, but there was no control group, and the 25,871-person VITAL trial found 2,000 IU a day did not reduce prostate cancer incidence.

    Studied dose
    800 to 2,000 IU vitamin D3 daily with food, adjusted to a 25-hydroxyvitamin D level of 30 ng/mL or above; pair with 1,000 to 1,200 mg total daily calcium from food plus supplement during ADT.
    Cautions
    Ask for a vitamin D level rather than guessing, and avoid pushing calcium above 1,500 mg a day from all sources, since very high calcium intake has been associated with more aggressive prostate cancer in cohort studies. Doses above 4,000 IU a day without monitoring risk high blood calcium, and thiazide diuretics raise that risk.
  2. Ginger

    Moderate evidence

    In a randomized trial of 576 people receiving chemotherapy, 0.5 to 1 g of ginger daily for 6 days starting 3 days before each cycle reduced acute nausea severity compared with placebo, on top of standard antiemetics; a higher 1.5 g dose worked less well. Later meta-analyses are mixed but lean toward a modest benefit for acute, not delayed, nausea. For men on docetaxel or cabazitaxel it is a reasonable low-risk add-on, not a replacement for prescribed antiemetics.

    Studied dose
    0.5 to 1 g of ginger root extract in capsules daily, split into two doses, beginning 3 days before chemotherapy and continuing 3 days after.
    Cautions
    Ginger has a mild antiplatelet effect, so mention it if you take warfarin, a DOAC or clopidogrel or have a low platelet count on chemotherapy. It can cause heartburn, and large amounts may lower blood sugar.
  3. Green Tea Extract

    Preliminary evidence

    In a 2006 Italian trial, 60 men with high-grade prostatic intraepithelial neoplasia (a precancerous finding) took 600 mg of green tea catechins or placebo daily for a year; 1 of 30 on catechins developed cancer versus 9 of 30 on placebo. A larger US trial of 97 men with the same lesions using 400 mg of EGCG daily found fewer cancers (5 versus 9) but the difference was not statistically significant. In men with established cancer, short pre-surgery courses lowered PSA slightly without clear clinical meaning. This is prevention-stage evidence only.

    Studied dose
    400 to 600 mg of green tea catechins (as decaffeinated extract standardized to EGCG) daily with food, roughly the amount in 4 to 6 cups of brewed green tea.
    Cautions
    Concentrated extracts above about 800 mg EGCG a day, especially on an empty stomach, have caused liver injury, so stop and get liver tests (ALT, AST) if you develop nausea, dark urine or jaundice. Green tea reduces absorption of the beta blocker nadolol and may blunt bortezomib, and the caffeine in non-decaffeinated extracts adds up.
  4. Sulforaphane

    Preliminary evidence

    In a French double-blind trial, 78 men with a rising PSA after radical prostatectomy took 60 mg of stabilized sulforaphane or placebo daily for 6 months. The primary endpoint, change in PSA at 6 months, narrowly missed significance, but PSA doubling time was 86 percent longer in the sulforaphane group (28.9 versus 15.5 months) and fewer men had a PSA rise of more than 20 percent. An earlier 20-man open-label study of 200 micromoles daily found a similar lengthening of doubling time in a minority. Slower PSA kinetics is a surrogate; no trial has shown fewer metastases or longer survival.

    Studied dose
    60 mg of stabilized free sulforaphane daily (as used in the trial), or 200 micromoles from a standardized broccoli sprout extract; roughly 100 g of fresh broccoli sprouts supplies a comparable amount.
    Cautions
    Well tolerated, with bloating and loose stools the main complaints. Broccoli sprout and glucoraphanin products vary widely in how much active sulforaphane they actually deliver, so choose one with a stated sulforaphane yield.
  5. Curcumin

    Preliminary evidence

    In 97 men on intermittent androgen deprivation, 1,440 mg of curcumin daily for 6 months during the off-treatment phase did not lengthen the primary endpoint, time to PSA progression, but the proportion whose PSA rose during that period was lower (10 percent versus 30 percent). A 40-man trial during external beam radiotherapy found 3 g of curcumin a day reduced urinary symptom severity. Both are small, single trials and there is no evidence curcumin shrinks tumors.

    Studied dose
    1,440 mg of curcumin daily in divided doses, as in the ADT trial; 3 g daily was used during radiotherapy. Formulations with piperine or phospholipids absorb better and need lower doses.
    Cautions
    Curcumin slows platelet function and adds to anticoagulant effect, can worsen gallstone pain, and piperine-containing products raise levels of many drugs. Because laboratory data suggest it can interfere with some chemotherapy and radiation effects, do not take it during active treatment without your oncologist's agreement, and stop it 2 weeks before surgery.

What matters day to day

  • Do resistance and aerobic exercise 3 or more days a week, especially during ADT: in the Health Professionals Follow-up Study, men with prostate cancer who did 3 or more hours of vigorous activity a week had a 61 percent lower risk of dying from it, and supervised resistance training in trials preserves muscle, lowers fatigue and limits the fat gain of hormone therapy.
  • Stop smoking: men who smoke at diagnosis have about a 60 percent higher risk of dying from prostate cancer and a higher risk of recurrence after treatment, and the excess fades about a decade after quitting.
  • Keep weight in the healthy range: obesity is linked to more aggressive disease, worse outcomes after surgery and a lower PSA that can delay detection, and losing weight on ADT is harder than preventing the gain.
  • Eat a plant-forward pattern with cooked tomatoes, cruciferous vegetables, fish, legumes and olive oil, and limit processed meat and high-fat dairy: cohort studies tie this pattern to lower rates of lethal disease, which is a better bet than any single nutrient in a capsule.
  • Keep every surveillance appointment if you are on active surveillance: about a third of men on surveillance are eventually treated because the cancer changed, and the strategy only works if PSA, MRI and biopsy are done on schedule.
  • If you start ADT, ask for a baseline bone density scan, a vitamin D level, a fasting glucose or A1c and a lipid panel, and repeat them yearly: hormone therapy drives bone loss, diabetes and cardiovascular risk that are easier to prevent than reverse.

Prevention

  • No proven prevention, but these may reduce risk:
  • Eating a diet rich in fruits, vegetables, and whole grains
  • Regular physical exercise
  • Maintaining a healthy weight
  • Discussing PSA screening benefits and risks with your doctor starting at age 50 (age 40–45 for high-risk men)

When to See a Doctor

  • Difficulty urinating, weak stream, or blood in urine
  • Pelvic, hip, or lower back pain that is new and persistent
  • Family history of prostate cancer — discuss screening timing
  • Elevated PSA level found on blood test

Frequently Asked Questions

References

  1. American Cancer Society. Cancer Facts & Figures 2025 (2025)
  2. Hamdy FC, Donovan JL, Lane JA, et al.. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine (2023)
  3. Klein EA, Thompson IM, Tangen CM, et al.. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011)
  4. US Preventive Services Task Force; Grossman DC, Curry SJ, Owens DK, et al.. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA (2018)
  5. Bettuzzi S, Brausi M, Rizzi F, et al.. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Research (2006)
  6. Cipolla BG, Mandron E, Lefort JM, et al.. Effect of Sulforaphane in Men with Biochemical Recurrence after Radical Prostatectomy. Cancer Prevention Research (2015)
  7. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the Health Professionals Follow-up Study. Journal of Clinical Oncology (2011)
  8. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA (2011)
  9. Ryan JL, Heckler CE, Roscoe JA, et al.. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Supportive Care in Cancer (2012)
  10. National Cancer Institute. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ), Patient Version (2024)View source

Related Conditions

Lab tests that relate to prostate cancer

Have questions about Prostate Cancer?

Ask Mother Nature AI for personalized, evidence-based guidance.

Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.